Protocol for a scoping review study on the prevalence and public health consequences of non-medical use (NMU) of tramadol in Africa

Authors:
Saidou Sabi Boun, et al.

Abstract

Background

Tramadol is one of the most prescribed painkillers in the world [1]. It is a synthetic opioid used for moderate to severe pain and is an excellent alternative to morphine due to its consistent availability and low price [2].

Initially, it was assessed as having common addictive properties, so it has not been placed under international control, like fentanyl and methadone, which are responsible for the opioid crisis in other parts of the world. In addition, physicians prefer it to non-steroidal anti-inflammatory drugs, as it is more tolerable and has fewer side effects [2, 3]. Tramadol is widely used for neuropathic and nociceptive pain, back pain, and people with cancer and is often prescribed for the pain of sickle cell anemia [4, 5]. It is considered an essential medicine and is included in the essential and generic medicines (EGM) list of many African countries, such as Botswana, Niger, Ghana, Mali, Côte d’Ivoire, Ghana, and Nigeria [2].

Several articles have reported an increase in the non-medical use (NMU) of tramadol, with the presence of addiction symptoms similar to those of morphine, especially when taken regularly at doses above therapeutic levels; however, this is becoming increasingly common [612]. Thus, in a few years, tramadol has become a public health problem in Africa in the same way as fentanyl has been responsible for the opioid crisis in the United States [13, 14]. Moreover, the enormous amounts of illicit drugs seized by the authorities in African countries establish a growing interest in this product, especially among the younger populations. For example, in 2014, 17 tonnes of smuggling were seized across West African countries, 121 tonnes in 2015 and 170 tonnes in 2017 [2]. The NMU of tramadol is all the more harmful as the illicit doses sold on the pavements and markets are 2 to 5 times higher than the usual doses (100 to 250 mg against 50 mg usually), thus increasing its addictive power [10, 11]. There are several reasons for the sudden increase in the popularity of tramadol among African youth. For example, the tablet is available everywhere in West Africa, in every “pharmacy on the floor.”

Unlike other products, it is sold in full view of health and political authorities. In addition, tramadol is sold for between 0.20 and 1 USD per 10-tablet pack, which is far less than other drugs [2]. This explains why it is described as the ’cocaine of the poor’ by some authors [11]. Conversely, compared to other drugs, marijuana is easier to transport and conceal, and the punishments incurred by sellers and possessors are less severe, leading to the population perceiving it as a medicine [15]. In most African countries, it is easy to obtain in pharmacies without a medical prescription [2]. In North African countries, a literature review showed that tramadol is the second most commonly used drug by students in Egypt due to its psychoactive properties [16] and more generally in countries in the Eastern Mediterranean region, including Libya, Morocco, Somalia and Tunisia [17]. In Central Africa, especially Cameroon, tramadol is used illicitly for its psychoactive properties and to increase work efficiency [18].

Tramadol is usually taken with tea, coffee, or alcohol, with other pharmaceutical drugs, such as benzodiazepines, in several African countries [9, 10]. It is consumed collectively during weddings, baptisms, during community work, for euphoric sensation seeking, which is one of the main reasons for its consumption [15]. It is also taken individually to combat fatigue by manual workers or in the search for physical or sexual performance [14, 15]. Its use is often associated with public disorder and traffic accidents due to potential side effects like dizziness, euphoria, and changes in fear and pain [15]. Due to the increased NMU of tramadol in many African countries, some authors describe the situation as an opioid crisis due to tramadol [13].

Despite the warning signs and numerous press articles on the health and social consequences of the NMU of tramadol [1922], more scientific studies are needed to circumscribe the extent and understand the health consequences of the phenomenon, as has been done in many parts of the world [23, 24]. Therefore, our scoping study aims to understand the nature and extent of tramadol NMU use and its health consequences in Africa to guide future research.

Methods

Protocol design

The study will be conducted according to the five methodological steps defined by Arksey and O’Malley (2005) and modified by Joanna Briggs Institute guidelines for conducting a scoping review to ensure systematic and repeatable studies [25]. The five steps are: 1) formulate the research question; 2) identify relevant studies; 3) select studies according to inclusion and exclusion criteria; 4) extract and map the results; 5) report the results [26] (Fig 1). The PRIMA-SCR (Preferred Reporting Items for Systematic Reviews and Meta-Analysis Extension for Scoping Reviews) checklist will be used to report, filter and communicate our results [27].

Stage 3: Selection of eligible studies

All articles in the scientific and grey literature related to the research question, our research framework, meeting our inclusion criteria and available in English or French in the selected databases will be included in the study. Our study will include all research conducted in Africa on the prevalence of NMU of tramadol in various population groups, evidence of addiction, intoxication, seizures, and mortality related to NMU of tramadol in a variety of formats such as original research, reviews, case reports, cohort or retrospective studies, and credible reports from international organizations involved in the control of NMU of tramadol.

All the articles derived from our search process will be uploaded to bibliographic data management software, such as EndNote 20, to delete duplicate research. The online Covidence platform will facilitate the screening of references [29], and two researchers will independently screen references at the title, abstract, and full-text screening stages. Any disagreements about the inclusion or exclusion of a study will be resolved by consensus, and when no agreement is reached, the third researcher will be consulted. The review will exclude: 1) studies without a specific indicator (prevalence, mortality, morbidity, etc.); 2) interventional and quasi-experimental studies because these studies involved tramadol NMU exposure manipulation. Also, our scoping review is not intended to include studies done in vitro to test tramadol addiction or toxicity; 3) studies in which tramadol is reported in combination with other drugs in such a way that it is not possible to specify isolated effects of tramadol; and 4) Texts and opinion literature.

Stage 5: Collating, summarizing, and reporting the results

As this is a scoping review, the quality of the included studies will not be assessed by the practice advocated by JBI and several other authors [25, 28, 30]. Our scoping review aims to explore the fields of knowledge related to the prevalence and the African subpopulations concerned by the phenomenon and to map the overall health consequences of tramadol NMU.

Prevalence will be reported narratively and linked to the categories of subpopulations concerned by tramadol NMU. The qualitative thematic analysis will allow us to answer the questions relative to the health consequence of tramadol NMU. Using the WHO International Classification of Diseases-11 (ICD-11), we identified three categories of medical conditions related to tramadol use:

  1. Intoxication is the set of conditions that follows the ingestion of tramadol, resulting in disturbances in the level of consciousness, cognition, perception, behaviour or other psycho-physiological function and responses. The troubles are directly linked to the pharmacological effect of tramadol and resolve with time, except where the medical complication occurs.
  2. Dependence syndrome: a cluster of behavioural, cognitive, and physiological phenomena that develop after repeated substance use. This includes a strong desire to take tramadol, difficulties controlling its use, persisting in its benefits despite harmful consequences, and prioritizing tramadol over other activities and obligations.
  3. Withdrawal symptoms: a group of variable clustering and severe symptoms occurring on absolute or relative tramadol withdrawal after persistent NMU. The onset and course are related to tramadol and the dose used immediately before cessation or reduction of use. Medical complications may complicate the withdrawal symptoms.

Discussion

The scoping review aims to investigate the prevalence, subpopulations affected, and health consequences of non-medical use of tramadol in African countries. To do this, two types of data will be gathered: quantitative data to show the phenomenon’s prevalence in different subpopulations and qualitative data to illustrate the health consequences of the NMU of tramadol. This study will not require approval from an ethics committee as the Scoping Review methodology involves reviewing and collecting data from publicly available materials. To disseminate the results, a thematic analysis will be conducted to better understand tramadol NMU’s health consequences. The results will be submitted for publication in a scientific journal and presented at relevant conferences such as the International Conference on Public Health in Africa (CPHA).

We anticipate certain limitations in our review. Firstly, it is possible that many locally conducted studies, which have not been published yet, may not be incorporated in this review. Secondly, since the phenomenon under study is hidden, the data collected through self-reporting or prevalence surveys may be prone to underreporting or social desirability bias. Furthermore, health is not only the absence of disease; thus, the consequences of the NMU of tramadol extend beyond health implications. The United Nations Office against Drugs and Crime (UNODC) has also highlighted tramadol NMU’s role in undermining the Sahel’s economies and security [14]. This link has been further confirmed by the Institute for Security Studies report, which focuses on the relationship between violent extremism and illicit activities in the so-called 3-border zone between Burkina Faso, Niger and Mali [31]. According to this report, two cases emerge from the attitude of armed groups regarding the nature or degree of their involvement in illicit activities: 1) they are sometimes beneficiaries of trafficking products such as tramadol, used as a stimulant for fighters of armed groups; 2) without being involved, they may derive income from illicit trafficking activities by levying taxes on convoys in their area of control, providing armed escorts, protection or transport of tramadol traffickers. Future research into the consequences of NMU of tramadol should include the social and economic impacts on the African population.

References

  1. 1.
    WHO. Critical review report: tramadol. 41st Expert Committee on Drug Dependence Meeting, Geneva: WHO; 2018. 51 p.
  2. 2.
    Klein A, Ane M, Madukwe AU, Dirisu O, Strijdom J, Kpatinvoh F, et al. Tramadol in Africa: Scarcity and Excess of Pain Medication in a Poorly Regulated Market. 2018.
  3. 3.
    Yorke E, Oyebola FO, Otene SA, Klein A. Tramadol: a valuable treatment for pain in Ghana and Nigeria. Current Medical Research and Opinion. 4 mai 2019;35(5):777–84. pmid:30782026
  4. 4.
    Lehmann KA. Le tramadol dans les douleurs aiguës. Drugs. 1 juin 1997;53(2):25–33.
  5. 5.
    Erhan E, Inal MT, Aydinok Y, Balkan C, Yegul I. Tramadol infusion for the pain management in sickle cell disease: a case report. Pediatric Anesthesia. janv 2007;17(1):84–6. pmid:17184440
  6. 6.
    Afshari R, Afshar R, Mégarbane B. Tramadol overdose: a review of the literature. Réanimation. sept 2011;20(5):436–41.
  7. 7.
    Bassiony MM, Abdelghani M, Salah El-Deen GM, Hassan MS, El-Gohari H, Youssef UM. Opioid Use Disorders Attributed to Tramadol Among Egyptian University Students. Journal of Addiction Medicine. mars 2018;12(2):150–5. pmid:29334513
  8. 8.
    Chikezie UE, Ebuenyi ID. Tramadol misuse in the Niger Delta; A review of cases presenting within a year. Journal of Substance Use. 3 sept 2019;24(5):487–91.
  9. 9.
    Maiga , Seyni H, Moussa AO, Sidikou A. Mesusage du tramadol par les adolescents et jeunes adultes en situation de rue. Pan African Medical Journal. 2012;13(1).
  10. 10.
    Maiga , Seyni H, Sidikou A, Azouma A. Crise convulsive chez les abuseurs de Tramadol et caféine: à propos de 8 cas et revue de la littérature. Pan African Medical Journal. 2012;13(24):7.
  11. 11.
    Tisseron A. Tramadol, médicament et drogue du pauvre en Afrique de l’Ouest et au Sahel. IFRI. Vol. 39. Afrique en questions; 2017. 4 p.
  12. 12.
    WHO. WHO Expert Committee on Drug Dependence: forty-first report [Internet]. Geneva: World Health Organization; 2019 [cité 30 oct 2022]. (WHO technical report series;1018). Disponible sur: https://apps.who.int/iris/handle/10665/325073
  13. 13.
    Klein A, Patwardhan S, Loglo MGA. Divergences and commonalities between the US opioid crisis and prescription medicine mis/use in West Africa. International Journal of Drug Policy. févr 2020;76:102640. pmid:31931438
  14. 14.
    Salm-Reifferscheidt L. Tramadol: Africa’s opioid crisis. Lancet. 2018 May 19;391(10134):1982–1983. pmid:29864013
  15. 15.
    Maiga , Seyni H, Sidikou A. Representations sociales de la consommation de tramadol au Niger, perceptions et connaissances des communautes: enjeux pour les actions de lutte. African Journal of Drug and Alcohol Studies. 2013;12(1).
  16. 16.
    Phing LTS, Aslam MS. A review study on tramadol abuse among egyptian university students. Journal of Pharmaceutical Research. 2020;5(1):53–7.
  17. 17.
    Mohaddes Ardabili H, Akbari A, Rafei P, Butner J, Khan R, Khazaal Y, et al. Tramadol, captagon and khat use in the Eastern Mediterranean Region: opening Pandora’s box. BJPsych Int. août 2022;19(3):58–62. pmid:36287793
  18. 18.
    Gallois S, van Andel TR, Pranskaityté G. Alcohol, drugs and sexual abuse in Cameroon’s rainforest. Social Science & Medicine. mai 2021;277:113929. pmid:33873011
  19. 19.
    Gigova R. Opioid tramadol destabilizes, fuels terror in parts of Africa, UN warns. CNN. 2017 [cité 17 janv 2023]; Disponible sur: https://www.cnn.com/2017/12/14/health/un-tramadol-trafficking-intl/index.html
  20. 20.
    Hay J. En Afrique, inquiétudes face à une jeunesse shootée au Tramadol. Marianne. 2018 [cité 17 janv 2023]; Disponible sur: https://www.marianne.net/monde/en-afrique-inquietudes-face-une-jeunesse-shootee-au-tramadol
  21. 21.
    Toulemonde M. Cocaïne, héroïne, tramadol… L’Afrique plus que jamais à l’épreuve du trafic de drogues. Jeune Afrique. 2021 [cité 17 janv 2023]; Disponible sur: https://www.jeuneafrique.com/1206814/politique/cocaine-heroine-tramadol-lafrique-plus-que-jamais-a-lepreuve-du-trafic-de-drogue/
  22. 22.
    Mateso M. Cameroun: des morts subites et des motards qui planent, quand l’addiction au tramadol vire au cauchemar. FranceInfo. 2019 [cité 17 janv 2023]; Disponible sur: https://www.francetvinfo.fr/monde/afrique/societe-africaine/cameroun-des-morts-subites-et-des-motards-qui-planent-quand-l-addiction-au-tramadol-vire-au-cauchemar_3624565.html
  23. 23.
    Rostam‐Abadi Y, Gholami J, Amin‐Esmaeili M, Safarcherati A, Mojtabai R, Ghadirzadeh MR, et al. Tramadol use and public health consequences in Iran: a systematic review and meta‐analysis. Addiction. 2020;115(12):2213–42. pmid:32196801
  24. 24.
    Iwanicki JL, Schwarz J, May KP, Black JC, Dart RC. Tramadol non-medical use in Four European countries: A comparative analysis. Drug and Alcohol Dependence. déc 2020;217:108367. pmid:33153831
  25. 25.
    Peters MD, Marnie C, Tricco AC, Pollock D, Munn Z, Alexander L, et al. Updated methodological guidance for the conduct of scoping reviews. JBI Evidence Synthesis [Internet]. 2020;18(10). Disponible sur: https://journals.lww.com/jbisrir/Fulltext/2020/10000/Updated_methodological_guidance_for_the_conduct_of.4.aspx pmid:33038124
  26. 26.
    Arksey H, O’Malley L. Scoping studies: towards a methodological framework. International journal of social research methodology. 2005;8(1):19–32.
  27. 27.
    Tricco AC, Lillie E, Zarin W, O’Brien KK, Colquhoun H, Levac D, et al. PRISMA Extension for Scoping Reviews (PRISMA-ScR): Checklist and Explanation. Ann Intern Med. 2 oct 2018;169(7):467–73. pmid:30178033
  28. 28.
    Peters MD, Godfrey C, McInerney P, Munn Z, Tricco AC, Khalil H. Chapter 11: scoping reviews (2020 version). JBI manual for evidence synthesis, JBI. 2020;2020.
  29. 29.
    Babineau J. Product review: Covidence (systematic review software). Journal of the Canadian Health Libraries Association/Journal de l’Association des bibliothèques de la santé du Canada. 2014;35(2):68–71.
  30. 30.
    Khalil H, Peters M, Godfrey CM, McInerney P, Soares CB, Parker D. An evidence‐based approach to scoping reviews. Worldviews on Evidence‐Based Nursing. 2016;13(2):118–23. pmid:26821833
  31. 31.
    Assanvo W, Dakono B, Théroux-Bénoni LA, Maïga I. Extrémisme violent, criminalité organisée et conflits locaux dans le Liptako-Gourma. Rapport pour l’Afrique de l’Ouest. 2019;26:10.

Source link